Is mefenamic acid indicated for the treatment of primary dysmenorrhea in women of reproductive age?

Is Mefenamic Acid Used for Dysmenorrhea?

Yes, mefenamic acid is FDA-approved and highly effective for treating primary dysmenorrhea in women of reproductive age, with a recommended dosing regimen of 500 mg initially followed by 250 mg every 6 hours starting at the onset of bleeding for 2-3 days. 1

FDA-Approved Indication

Mefenamic acid is specifically indicated by the FDA for the treatment of primary dysmenorrhea 1. The drug label explicitly states this as one of only two approved indications (the other being mild to moderate pain). This represents the highest level of regulatory endorsement for this use.

Recommended Dosing Protocol

For primary dysmenorrhea, initiate 500 mg at the onset of bleeding and associated symptoms, followed by 250 mg every 6 hours orally 1. Clinical studies demonstrate that:

• Treatment should begin with the start of menses
• Effective treatment typically requires only 2-3 days
• This short-duration approach minimizes exposure while maximizing efficacy

Evidence Supporting Use

Clinical Efficacy

Multiple controlled trials demonstrate mefenamic acid's superiority over placebo for dysmenorrhea 1, 2. In a pivotal double-blind crossover study, mefenamic acid was significantly superior to placebo across all parameters including:

• Pain assessment by both patient and investigator
• Reduced need for concurrent analgesic medication
• Decreased frequency and severity of dysmenorrhea symptoms 1

One study showed complete relief in 88.6% of patients across all treated cycles, with moderate relief in an additional 5.7% 2.

Comparative Effectiveness

When compared to other NSAIDs, mefenamic acid demonstrates comparable efficacy:

• Versus ibuprofen: A systematic review found both drugs superior to placebo, with no significant difference between them 3
• Versus celecoxib: A 2020 randomized crossover trial showed comparable pain relief and quality of life improvements 4
• Versus etoricoxib: One study suggested etoricoxib may provide superior pain relief, though mefenamic acid remained effective 5

Guideline Support

The 2024 CDC Selected Practice Recommendations for Contraceptive Use explicitly lists mefenamic acid as a treatment option for bleeding irregularities in contraceptive users 6. While this context differs from primary dysmenorrhea, it demonstrates recognition of mefenamic acid's role in managing menstrual-related symptoms. Earlier 2013 guidelines similarly cited evidence that mefenamic acid (500 mg three times daily for 5 days) significantly stopped bleeding within 7 days compared to placebo [7-7].

Clinical Algorithm for Use

When to prescribe:

1. Confirmed primary dysmenorrhea (exclude secondary causes)
2. Women ≥14 years of age
3. No contraindications to NSAIDs (GI bleeding risk, renal impairment, hepatic dysfunction)

How to prescribe:

1. Start 500 mg at onset of bleeding or pain (whichever comes first)
2. Continue 250 mg every 6 hours as needed
3. Limit to 2-3 days per cycle
4. Take with food to minimize GI side effects

When to reconsider:

• If no improvement after 2-3 cycles, evaluate for secondary dysmenorrhea
• If side effects occur (though generally well-tolerated 1)
• If patient has renal or hepatic impairment (dose adjustment or alternative needed 1)

Important Safety Considerations

Critical warnings from the FDA label:

• Use the lowest effective dose for the shortest duration 1
• Should not exceed one week for pain indications (though dysmenorrhea typically requires only 2-3 days)
• Contraindicated in patients with pre-existing renal disease or significantly impaired renal function 1
• Patients with hepatic dysfunction may require dose reduction 1
• Standard NSAID warnings apply regarding GI bleeding, cardiovascular risk, and renal toxicity

Common pitfall: Prescribing for longer than necessary. The evidence clearly shows 2-3 days of treatment per cycle is sufficient 1, and prolonged use increases risk without additional benefit.

Quality of Life Impact

Studies demonstrate that effective treatment with mefenamic acid improves quality of life scores in women with primary dysmenorrhea 4. This addresses not just pain but the broader impact on daily functioning, work attendance, and overall well-being—outcomes that matter most to patients.